Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study

References

• Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–9. doi:10.1056/NEJMoa1606774.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers S, Salman P, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378:2093–2104. doi:10.1056/NEJMoa1801946.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028. doi:10.1056/NEJMoa1501824.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob -J-J, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–1356. doi:10.1056/NEJMoa1709684.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290. doi:10.1056/NEJMoa1712126.
   PubMed Web of Science ®Google Scholar
• Kang YK, Boku N, Satoh T, Ryu M-H, Chao Y, Kato K, Chung HC, Chen J-S, Muro K, Kang WK, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–2471. doi:10.1016/S0140-6736(17)31827-5.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein BG, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867. doi:10.1056/NEJMoa1602252.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im S-A, Shaw Wright G, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–2121. doi:10.1056/NEJMoa1809615.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639. doi:10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P,  Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E,et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–135. doi:10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. doi:10.1016/S0140-6736(16)32517-X.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–2092. doi:10.1056/NEJMoa1801005.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. doi:10.1056/NEJMoa1716948.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040–2051. doi:10.1056/NEJMoa1810865.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:198–211. doi:10.1016/S1470-2045(20)30641-0.
   PubMed Web of Science ®Google Scholar
• Roch B, Coffy A, Jean-Baptiste S, Palaysi E, Daures J-P, Pujol J-L, Bommart S. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer. 2020;143:19–26. doi:10.1016/j.lungcan.2020.03.003.
   PubMed Web of Science ®Google Scholar
• Miyawaki T, Naito T, Kodama A, Nishioka N, Miyawaki E, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Wakuda K, et al. Desensitizing effect of cancer cachexia on immune checkpoint inhibitors in patients with advanced NSCLC. JTO Clin Res Rep. 2020;1:100020. doi:10.1016/j.jtocrr.2020.100020.
   PubMedGoogle Scholar
• Turcott JG, Martinez-Samano JE, Cardona AF, Bassarmal SS, Ramírez-Tirado LA, Zatarain-Barrón ZL, Barrón F, Corrales L, Martín C, Barragán-Castillo PA, et al. The role of Cachexia Grading System in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: implications for Survival. Nutr Cancer. 2021;73:794–801. doi:10.1080/01635581.2020.1769691.
   PubMed Web of Science ®Google Scholar
• Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793–799. doi:10.1016/j.clnu.2008.06.013.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–495. doi:10.1016/S1470-2045(10)70218-7.
   PubMed Web of Science ®Google Scholar
• Yoshioka H, Shimokawa M, Seto T, Morita S, Yatabe Y, Okamoto I, Tsurutani J, Satouchi M, Hirashima T, Atagi S,et al. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol. 2019;30:1978–1984. doi:10.1093/annonc/mdz399.
   PubMed Web of Science ®Google Scholar
• Fujimoto D, Miura S, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Yokoi T, Asao T, Tamiya M, Nakamura A, et al. Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: a multicentre, retrospective cohort study. Eur J Cancer. 2021;150:63–72. doi:10.1016/j.ejca.2021.03.016.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–458. doi:10.1038/bmt.2012.244.
   PubMed Web of Science ®Google Scholar
• Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hütterer E, Isenring E, Kaasa S,et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36:11–48. doi:10.1016/j.clnu.2016.07.015.
   PubMed Web of Science ®Google Scholar
• Vanhoutte G, van de Wiel M, Wouters K, Sels M, Bartolomeeussen L, De Keersmaecker S, Verschueren C, De Vroey V, De Wilde A, Smits E, et al. Cachexia in cancer: what is in the definition? BMJ Open Gastroenterol. 2016;3:e000097. doi:10.1136/bmjgast-2016-000097.
   PubMed Web of Science ®Google Scholar
• Anderson LJ, Albrecht ED, Garcia JM. Update on management of cancer-related cachexia. Curr Oncol Rep. 2017;19(1):3. doi:10.1007/s11912-017-0562-0.
   PubMed Web of Science ®Google Scholar
• Lacour M, Hiltbrunner S, Lee SY, Soltermann A, Rushing EJ, Soldini D, Weder W, Curioni-Fontecedro A. Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence. Clin Lung Cancer. 2019;20:391–396. doi:10.1016/j.cllc.2019.05.013.
   PubMed Web of Science ®Google Scholar
• Lau SKM, Gannavarapu BS, Carter K, Gao A, Ahn C, Meyer JJ, Sher DJ, Jatoi A, Infante R, Iyengar P, et al. Impact of Socioeconomic Status on Pretreatment Weight Loss and Survival in Non-Small-Cell Lung Cancer. J Oncol Pract. 2018;14:e211–20. doi:10.1200/JOP.2017.025239.
   PubMed Web of Science ®Google Scholar
• Takeda M, Kasai T, Naito M, Tamiya A, Taniguchi Y, Saijo N, Naoki Y, Okishio K, Shimizu S, Kojima K, et al. Programmed death-ligand 1 expression with clone 22C3 in non-small cell lung cancer: a single institution experience. Clin Med Insights Oncol. 2019;13:1179554918821314. doi:10.1177/1179554918821314.
   Web of Science ®Google Scholar
• Li C, Liu J, Xie Z, Zhu F, Cheng B, Liang H, Li J, Xiong S, Chen Z, Liu Z, et al. PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China. Ther Adv Med Oncol. 2020;12:1758835920965840. doi:10.1177/1758835920965840.
   Web of Science ®Google Scholar
• Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10. doi:10.1186/s12943-018-0928-4.
   PubMed Web of Science ®Google Scholar
• Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14(1):10. doi:10.1186/s13045-020-01027-5.
   PubMed Web of Science ®Google Scholar
• Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4(1):17105. doi:10.1038/nrdp.2017.105.
   PubMed Web of Science ®Google Scholar
• Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019;30(2):219–235. doi:10.1093/annonc/mdy551.
   PubMed Web of Science ®Google Scholar
• Li JY, Chen YP, Li YQ, Liu N, Ma J. Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. Mol Cancer. 2021;20:27. doi:10.1186/s12943-021-01317-7.
   PubMed Web of Science ®Google Scholar
• Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2012;10:90–99. doi:10.1038/nrclinonc.2012.209.
   PubMed Web of Science ®Google Scholar
• Kimura M, Naito T, Kenmotsu H, Taira T, Wakuda K, Oyakawa T, Hisamatsu Y, Tokito T, Imai H, Akamatsu H, et al. Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer. 2015;23(6):1699–1708. doi:10.1007/s00520-014-2534-3.
   PubMed Web of Science ®Google Scholar
• Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14(11):754–762. doi:10.1038/nrc3829.
   PubMed Web of Science ®Google Scholar
• Le-Rademacher J, Lopez C, Wolfe E, Foster NR, Mandrekar SJ, Wang X, Kumar R, Adjei A, Jatoi A. Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients. J Cachexia Sarcopenia Muscle. 2020;11:1501–1508. doi:10.1002/jcsm.12625.
   PubMed Web of Science ®Google Scholar
• Takayama K, Atagi S, Imamura F, Tanaka H, Minato K, Harada T, Katakami N, Yokoyama T, Yoshimori K, Takiguchi Y, et al. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study. Support Care Cancer. 2016;24:3473–3480. doi:10.1007/s00520-016-3156-8.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Ricciuti B, Tiseo M, Bria E, Banna GL, Aerts JG, Barbieri F, Giusti R, Cortinovis DL, Migliorino MR, et al. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. J Immunother Cancer. 2020;8(2):e001403. doi:10.1136/jitc-2020-001403.
   PubMed Web of Science ®Google Scholar
• Antoun S, Morel H, Souquet P-J, Surmont V, Planchard D, Bonnetain F, Foucher P, Egenod T, Krakowski I, Gaudin H, et al. Staging of nutrition disorders in non-small-cell lung cancer patients: utility of skeletal muscle mass assessment. J Cachexia Sarcopenia Muscle. 2019;10(4):782–793. doi:10.1002/jcsm.12418.
   PubMed Web of Science ®Google Scholar